|
|
|
European Biopharmaceutical Review
|
Personalised medicine means that medical treatment can be tailored towards an individual after a disease has been – hopefully correctly – diagnosed. The treatment should take multiple factors such as age, weight, lifestyle, and, ultimately, genomic information into account. The more precisely and reliably this can be done, the better the patient should respond to the therapy without any unwanted adverse effects.
Nowadays, the term ‘personalised medicine’ is almost exclusively associated with next generation sequencing (NGS) or whole genome sequencing (WGS), respectively. This means one essentially takes a sample (a simple stick in the mouth serves this purpose well) and sends it to their favourite NGS company, which will probably cost less than €1,000, and then they get a long list of diseases and a probability that they will develop one of these diseases or they already have one or multiple diseases. However, that is not the whole story, and, probably, the more interesting story starts there.
A Brief History of WGS
At the beginning in 1990, sequencing the entire human genome for the first time took 13 years and $3 billion. Nine years later, 69 more human genomes were sequenced. In 2016, the University of Toronto launched a project to sequence 10,000 genomes within one year (1). As of the beginning of 2018, the 100,000 genomes project has reached almost 40,000 sequenced genomes and is expected to reach its goal by end of the same year (2). When you look at the cost for sequencing a genome (see Figure 1, page 54, noting the logarithmic y-scale), it becomes clear what a tremendous progress the whole technique has made over the past few years. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
PCI Pharma Services Completes Acquisition of Sherpa Clinical Packaging
Philadelphia, USA – October 2, 2018 Leading global biopharmaceutical outsourcing services provider PCI Pharma Services (PCI) has announced the completion of its acquisition of Sherpa Clinical Packaging (Sherpa).
More info >> |
|
 |
White Papers |
 |
|
8 Ways To Reduce Tablet Manufacturing Costs
Natoli Engineering Company, Inc.
It’s no surprise that in today’s economy, companies are facing budget cuts across the board. In an effort to address these challenges, this list of 8 Ways to Reduce Tablet Manufacturing Costs was compiled.
More info >> |
|
 |
Industry Events |
 |
CPhI & P-MEC India 2018
12-14 December 2018, India Expo Mart, New Delhi, India
CPhI & P-MEC India (December 12-14, 2018) – organised by UBM (part
of Informa PLC) – announces that the 12th edition of Asia’s
largest Pharma exhibition is moving to the India Expo Mart, New Delhi. The new
venue will see the exhibition now hosted in a single venue, bringing it closer
to the Indian regulatory and legislative capital. New Delhi is also the
country’s main international transport hub and will encourage an increased
international attendance. In total, more than 50,000 people from 122 countries
are expected, along with nearly 1,500 exhibitors.
More info >> |
|
|
